middle.news
ReNerve builds sales momentum as NervAlign study nears completion
1:20pm on Monday 5th of October, 2026 AEDT
•
Medical Devices and Healthcare
Read Story
ReNerve builds sales momentum as NervAlign study nears completion
1:20pm on Monday 5th of October, 2026 AEDT
Key Points
Annual revenue up 88%
Quarterly sales increased more than 50% from the previous quarter
$1.48 million cash at 30 June
$5 million RiverFort funding facility signed in July
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Renerve (ASX:RNV)
OPEN ARTICLE